AR004972A1 - Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado. - Google Patents

Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.

Info

Publication number
AR004972A1
AR004972A1 ARP960105317A ARP960105317A AR004972A1 AR 004972 A1 AR004972 A1 AR 004972A1 AR P960105317 A ARP960105317 A AR P960105317A AR P960105317 A ARP960105317 A AR P960105317A AR 004972 A1 AR004972 A1 AR 004972A1
Authority
AR
Argentina
Prior art keywords
alkyl
aminocarbonyl
amino
optionally substituted
group
Prior art date
Application number
ARP960105317A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI952461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of AR004972A1 publication Critical patent/AR004972A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP960105317A 1995-11-24 1996-11-25 Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado. AR004972A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI952461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici

Publications (1)

Publication Number Publication Date
AR004972A1 true AR004972A1 (es) 1999-04-07

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105317A AR004972A1 (es) 1995-11-24 1996-11-25 Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.

Country Status (26)

Country Link
US (1) US6277862B1 (enExample)
EP (1) EP0876347B1 (enExample)
JP (1) JP2000501104A (enExample)
KR (1) KR19990071597A (enExample)
CN (1) CN1207730A (enExample)
AP (1) AP9801237A0 (enExample)
AR (1) AR004972A1 (enExample)
AT (1) ATE289994T1 (enExample)
BG (1) BG102558A (enExample)
BR (1) BR9611820A (enExample)
CA (1) CA2238298A1 (enExample)
CZ (1) CZ157998A3 (enExample)
DE (1) DE69634416T2 (enExample)
EA (1) EA002124B1 (enExample)
ES (1) ES2236757T3 (enExample)
IL (1) IL124522A0 (enExample)
MX (1) MX9804107A (enExample)
NO (1) NO311212B1 (enExample)
NZ (1) NZ323387A (enExample)
OA (1) OA11010A (enExample)
PL (1) PL326967A1 (enExample)
SK (1) SK66798A3 (enExample)
TR (1) TR199800924T2 (enExample)
TW (1) TW353066B (enExample)
UY (1) UY24733A1 (enExample)
WO (1) WO1997021680A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007751A1 (en) 1991-10-18 1993-04-29 Monsanto Company Fungicides for the control of take-all disease of plants
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
US6413982B1 (en) 1999-03-29 2002-07-02 Neurogen Corporation 4-substituted quinoline derivatives
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
JP2004525184A (ja) * 2001-04-11 2004-08-19 グラクソスミスクライン・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしての3−置換キノリン−4−カルボキサミド誘導体
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DK1911763T3 (da) 2003-01-28 2010-11-15 Ironwood Pharmaceuticals Inc Sammensætninger til behandling af mavetarmsygdomme
GB0303086D0 (en) 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
SG155229A1 (en) * 2004-11-09 2009-09-30 Smithkline Beecham Corp Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
WO2007018466A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Alkylpyridyl quinolines as nk3 receptor modulators
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EA201000392A1 (ru) * 2007-09-28 2010-10-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
CN101932557A (zh) * 2007-09-28 2010-12-29 葛兰素史密丝克莱恩有限责任公司 糖原磷酸化酶抑制剂化合物及其药物组合物
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3939964A1 (en) 2008-12-31 2022-01-19 Ardelyx, Inc. Combinations for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN104902930A (zh) 2012-08-21 2015-09-09 阿德利克斯公司 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2909169A1 (en) 2013-04-12 2014-10-16 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
EP2986293A1 (en) 2013-04-19 2016-02-24 Astrazeneca AB A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
EP3565811A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS63119455A (ja) * 1986-06-27 1988-05-24 Nippon Shinyaku Co Ltd グリシン誘導体
RO114445B1 (ro) * 1994-05-27 1999-04-30 Smithkline Beecham S.P.A. Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
EP0876347A1 (en) 1998-11-11
NO311212B1 (no) 2001-10-29
US6277862B1 (en) 2001-08-21
TW353066B (en) 1999-02-21
BG102558A (bg) 1999-03-31
MX9804107A (es) 1998-09-30
NZ323387A (en) 2000-02-28
DE69634416D1 (de) 2005-04-07
BR9611820A (pt) 1999-07-13
CA2238298A1 (en) 1997-06-19
ATE289994T1 (de) 2005-03-15
EA002124B1 (ru) 2001-12-24
EP0876347B1 (en) 2005-03-02
WO1997021680A1 (en) 1997-06-19
NO982331L (no) 1998-07-22
CZ157998A3 (cs) 1998-12-16
CN1207730A (zh) 1999-02-10
TR199800924T2 (xx) 1998-08-21
ES2236757T3 (es) 2005-07-16
KR19990071597A (ko) 1999-09-27
JP2000501104A (ja) 2000-02-02
DE69634416T2 (de) 2005-12-29
OA11010A (en) 2003-03-06
AP9801237A0 (en) 1998-06-30
NO982331D0 (no) 1998-05-22
UY24733A1 (es) 2001-08-27
PL326967A1 (en) 1998-11-09
EA199800477A1 (ru) 1998-12-24
IL124522A0 (en) 1998-12-06
SK66798A3 (en) 1999-01-11

Similar Documents

Publication Publication Date Title
AR004972A1 (es) Compuesto quinolino 4-carboxamidas n-sustituidas, un procedimiento para su preparacion, el uso de los mismos para la fabricacion de un medicamento, una composicion farmaceutica y un antagonista nk-2/nk-3 combinado.
AR004735A1 (es) Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
AR039127A1 (es) Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
BR9915475A (pt) Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
EA200401431A1 (ru) Производные триазола в качестве антагонистов рецептора тахикинина
AR037676A1 (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion; composicion farmaceutica que los comprende y procedimiento para preparar compuestos de formula (i)
AR049443A1 (es) Derivados de pirrolpiridinas
BR9809652A (pt) Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
EA200200912A1 (ru) Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR060729A1 (es) Compuestos agonistas de los receptores muscarinicos
HRP20000896B1 (en) Adenosine derivatives
AR045879A1 (es) Uso de un antagonista del receptor nk3 para preparar una composicion farmaceutica
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
SE0101579D0 (sv) New compounds
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR037611A1 (es) Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
ATE348813T1 (de) Chinolinderivate als nk-2 und nk-3 rezeptor- liganden
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
AR064137A1 (es) Derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona,antagonistas de receptores de vasopresina v1a,metodo de obtencion,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos coronarios,depresivos y otras enfe
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal